Literature DB >> 22687814

Rasburicase for huge hepatocellular carcinoma with tumor lysis syndrome: case report.

Chia-Ter Chao1, Chih-Kang Chiang.   

Abstract

OBJECTIVE: To report a case of huge hepatocellular carcinoma associated with tumor lysis syndrome and its management. CLINICAL PRESENTATION AND INTERVENTION: A 51-year-old hepatitis B carrier visited our clinic with progressive weight loss over recent months. Abdominal ultrasonography and magnetic resonance imaging revealed a huge hepatic mass in a cirrhotic liver, identified as hepatocellular carcinoma. A hepatologist and surgeon recommended transarterial chemoembolization followed by hepatectomy. The patient underwent the procedure, with the complication of tumor lysis syndrome. He was treated with a single high dose (9 mg) of rasburicase and his clinical condition improved dramatically, with acute kidney injury subsiding without emergent hemodialysis.
CONCLUSIONS: This was a case of hepatocellular carcinoma with tumor lysis syndrome and acute kidney injury, treated successfully with rasburicase.
Copyright © 2012 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22687814     DOI: 10.1159/000339083

Source DB:  PubMed          Journal:  Med Princ Pract        ISSN: 1011-7571            Impact factor:   1.927


  4 in total

Review 1.  Tumor lysis syndrome and primary hepatic malignancy: case presentation and review of the literature.

Authors:  Sean P Zivin; Youssef Elias; Charles E Ray
Journal:  Semin Intervent Radiol       Date:  2015-03       Impact factor: 1.513

Review 2.  Tumor lysis syndrome: new challenges and recent advances.

Authors:  F Perry Wilson; Jeffrey S Berns
Journal:  Adv Chronic Kidney Dis       Date:  2014-01       Impact factor: 3.620

Review 3.  Tumor Lysis Syndrome in Solid Tumors: An up to Date Review of the Literature.

Authors:  Aibek E Mirrakhimov; Alaa M Ali; Maliha Khan; Aram Barbaryan
Journal:  Rare Tumors       Date:  2014-06-13

4.  Spontaneous tumor lysis syndrome in a patient with metastatic hepatocellular carcinoma.

Authors:  Raman Mehrzad; Hiroki Saito; Zachary Krahn; Alexander Feinstein
Journal:  Med Princ Pract       Date:  2014-03-07       Impact factor: 1.927

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.